XYRA Wins Patent for AFib Drug Targeting Heart Failure Patients

LOS ALTOS, CA – March 04, 2026 – In a move that could reshape treatment for millions, private biopharmaceutical company XYRA LLC announced today that it has been issued a U.S. patent for a novel therapy aimed at one of the most challenging intersections in cardiac medicine: atrial fibrillation in patients with heart failure. The patent protects the use of its investigational drug, budiodarone, in a dose-adjusted, monitored regimen designed to control the dangerous arrhythmia without worsening the underlying heart failure—a critical flaw in many existing medications.

Atrial fibrillation (AFib), the most common sustained heart rhythm disorder affecting an estimated 44 million people worldwide, is a well-known precursor to stroke. However, its relationship with heart failure is a particularly devastating feedback loop. AFib can cause or worsen heart failure, and heart failure often leads to AFib. This combination creates a high-risk population of patients who are notoriously difficult to treat, facing a five-fold increased risk of stroke, hospitalization, and death. The new patent, No. 12,551,706, positions XYRA to address this significant unmet medical need with a therapy that promises not just efficacy, but a new level of safety for this vulnerable group.

The Vicious Cycle of Cardiac Disease

The challenge of treating patients with both AFib and heart failure is a daily reality in cardiology. The loss of coordinated atrial contraction during an AFib episode can reduce cardiac output, putting immense strain on an already weakened heart. Studies show that up to 40% of patients hospitalized for AFib also have heart failure. Yet, the tools available to physicians are often a double-edged sword.

Many standard anti-arrhythmic drugs used to restore a normal heart rhythm (rhythm control) work by mechanisms that can also suppress the heart's pumping function, or ventricular function. For a patient whose heart is already struggling, these drugs are often contraindicated, as they risk precipitating or exacerbating acute heart failure. This leaves physicians with limited options, often forcing a choice between controlling the arrhythmia and protecting the heart's mechanical function.

Drugs like flecainide and propafenone, for example, are generally avoided in patients with structural heart disease. Even dronedarone, a more modern drug, is contraindicated in patients with recently decompensated heart failure. Amiodarone, while effective and often used in heart failure patients, is considered a last resort by many due to its long half-life, tendency to accumulate in tissues, and a formidable list of potential side effects affecting the lungs, liver, and thyroid. This creates a therapeutic gap for a large and growing patient population, with an estimated 7-10% of AFib patients developing heart failure each year.

A Novel Drug with a Differentiated Profile

Budiodarone, XYRA's lead candidate, is engineered to break this cycle. Currently in Phase 3 studies, it is a potentially first-in-class mixed ion channel blocker that, while a chemical analogue of amiodarone, possesses a fundamentally different metabolic profile. It is broken down by esterases in the body, giving it a significantly shorter half-life. Crucially, animal and human studies have shown no evidence of the tissue accumulation that makes amiodarone a long-term risk.

Its most significant advantage, however, lies in what it doesn't do. According to company data, budiodarone does not depress ventricular function. This key feature means it could be safely used to manage AFib in patients with existing heart failure, offering a rhythm control strategy without the prohibitive risks of many current anti-arrhythmics. By reducing the frequency and duration of AFib episodes—known as reducing AF burden (AFB) and eliminating long episodes of AF (LEAF)—the drug aims to restore normal sinus rhythm and, with it, the vital contribution of atrial contraction to cardiac output. This could not only alleviate symptoms but also potentially slow or reverse the progression of heart failure itself.

The Dawn of Personalized AFib Management

Beyond the drug's chemical properties, the newly issued patent protects an equally innovative therapeutic method: a personalized approach that integrates the medication with modern wearable technology. XYRA's strategy envisions doctors adjusting budiodarone dosage based on data from FDA-approved AFib monitoring devices, such as smartwatches and patch monitors from companies like Apple, Fitbit, and AliveCor.

This synergy between pharmacology and digital health represents a significant step forward in cardiac care. The widespread availability of these consumer and medical-grade devices makes it possible to continuously track a patient's AFib burden outside the clinic. This data can guide physicians in titrating the drug dose upward to achieve optimal rhythm control, confirming both patient compliance and therapeutic response in a way that mirrors the successful management of other chronic conditions like hypertension.

The FDA has shown receptiveness to this modern paradigm, having reached an agreement with XYRA on using these monitoring devices in the pivotal Phase 3 trials and issuing guidance on how such technology can be incorporated into a drug's official label. This suggests a regulatory pathway that embraces data-driven, individualized treatment over a one-size-fits-all dosing regimen.

Navigating the High-Stakes Path to Approval

With patent protection secured, XYRA is focused on the final and most expensive stage of drug development. The company is advancing budiodarone in a robust Phase 3 program, which includes an open-label study where dosage will be titrated using data from wearables, and a large, six-month, double-blind, placebo-controlled trial to confirm its efficacy and safety.

Leading the charge is Dr. Peter Milner, a seasoned cardiologist and biotech entrepreneur with a track record of success. As a co-founder of CV Therapeutics, which was acquired by Gilead for $1.5 billion, and ARYx Therapeutics, which he took public, Dr. Milner has extensive experience shepherding novel cardiovascular drugs from concept to market.

"In recent years, there has been a marked growth in both atrial fibrillation and heart failure, which are integrally related and difficult to treat," said Dr. Milner in the company's press release. "We plan to investigate the use of monitored, dose-adjusted budiodarone in Phase 3 clinical trials as an effective, safe, and well-tolerated treatment option... to reduce the development of heart failure in at-risk AF patients."

This strategic intellectual property win provides XYRA with a crucial competitive advantage in a high-stakes market. Should the Phase 3 trials prove successful, budiodarone would not be just another anti-arrhythmic drug; it would be a tailored solution for a population that has been largely excluded from the benefits of modern rhythm control therapy. For millions of patients and the clinicians who treat them, the outcome of these trials represents a new frontier of hope against two of the heart's most formidable diseases.